| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 57
| Issue : 2 | Page : 86-90 |
|
|
Prevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study
Christian Obirikorang1, Lawrence Quaye2, James Osei-Yeboah3, Enoch Anto Odame1, Isaac Asare4
1 Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2 Department of Biomedical Laboratory Sciences, School of Medicine and Health Sciences, University of Development Studies, Tamale, Ghana
3 Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana
4 Department of Medical Laboratory Technology, Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
Correspondence Address:
Christian Obirikorang
Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi
Ghana
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0300-1652.182082
|
|
|
Background: Prevalence of metabolic syndrome (MetS) in HIV-infected patients is very limited in the Ghanaian setting and may vary across the globe by the different study populations and criteria used.
Aim: We investigated the prevalence of MetS among HIV-infected patients receiving highly active antiretroviral therapy (HAART) at the St. Dominic Hospital, Akwatia, Ghana. Patients and Methods: This cross-sectional study recruited 433 HIV-infected patients (294 on HAART and 139 HAART-naÏve) from the period of February 2013 to December 2013. Information on the demographic, clinical, anthropometric characteristics were obtained and lipid profile for each patient was assessed. MetS was assessed based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III), World Health Organization (WHO) and International Diabetes Federation (IDF) criteria. Results: The prevalence of MetS was 24.5% according to WHO criteria, 48.3% by NCEP-ATP III criteria, and 42.3% by IDF criteria. In general, participants on HAART were significantly associated with higher prevalence of MetS compared to those without HAART (P < 0.05) irrespective of the criteria used. Prevalence of clustering components of MetS was significantly higher among those on HAART when risk scores of 2 and above were used compared with those not on HAART (P < 0.05). Conclusion: HAART recipient developed MetS as indicated by dyslipidemia, high blood pressure, and abnormal body fat. It is incumbent on health giver to incorporate MetS assessment as a part of treatment and management plan in patients receiving HAART. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
